Hi
I am 64 and was diagnosed in 2015 and had radiotherapy in 2016 followed by Zoladex injections. In 2020 had slight rise in PSA and had PET scan which showed tumour in a lymph node in left groin. This led to SABR and bicalutamide added. PSA came down to 0.15 last July but last week rose to 3.5. I’m now worried about where this leaves me and what options are left. Cheers.
OK. Rather surprised that there has not been a PSA test in the interim as this would have provided a useful reference point to help judge progress. I wouldn't rule out a urine test or another PSA test being done or a scan first and a way forward being determined after that but it depends on how your Oncologist, who has your detailed histology considers it. Not very long now before you know more. Do keep us informed.
Edited by member 13 Feb 2022 at 02:00 | Reason: simplification
It may be that your cancer has learned how to survive without testosterone - this is known as being hormone refractory or castrate resistant. It is also possible that the cancer has started using the bicalutimide as food. Still lots of treatment options - the oncologist might begin by simply stopping the bicalutimide - the PSA might drop sharply. Next options include enzalutimide, abiraterone or chemotherapy but you will probably keep on having the Zoladex alongside. As Barry says, a scan to see where the active cells are would be very helpful
Edited by member 12 Feb 2022 at 23:06 | Reason: Not specified
I have an update. My bone scan was clear but the CT showed a 14mm growth on a lymph node in my pelvic area. I was initially told I would start steroids but the consultant has decided to send me for another PET scan with a view to having another course of SABR if it is suitable. He also stopped my bicalutamide. A bit more waiting involved and a 110 mile round trip for the PET and again for each of the SABR sessions if they go ahead but I feel a lot better about it all now. Cheers.
Best wishes,
Chris
Click through to become a member and gain access to support, information and real time replies.